Rhythm Metabolic racks up $40 mln Series A

Boston-based Rhythm Metabolic, a subsidiary of Rhythm, has closed $40 million in Series A funding. The investors included OrbiMed, Deerfield Management, Wellington Management Company, MPM Capital, New Enterprise Associates, Third Rock Ventures, Pfizer Ventures and Ipsen. In conjunction with the funding, Jonathan Silverstein of OrbiMed has been appointed to Rhythm Metabolic's board of directors. Rhythm Metabolic is focused on treating obesity caused by genetic deficiencies.

North AmericaUSBriefs